Correction to: Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1435-5922
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy ; volume:57 ; number:11 ; day:17 ; month:9 ; year:2022 ; pages:827 ; date:11.2022
Journal of gastroenterology ; 57, Heft 11 (17.9.2022), 827, 11.2022
- Creator
-
Kawakubo, Kazumichi
Fernández-del Castillo, Carlos
Liss, Andrew Scott
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00535-022-01922-3
- URN
-
urn:nbn:de:101:1-2023011021074704872019
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kawakubo, Kazumichi
- Fernández-del Castillo, Carlos
- Liss, Andrew Scott
- SpringerLink (Online service)
Other Objects (12)
Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy
Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
Epigenetic regulation and role of metastasis suppressor genes in pancreatic ductal adenocarcinoma
Epigenetic regulation and role of metastasis suppressor genes in pancreatic ductal adenocarcinoma
Cellular immunotherapy of pancreatic ductal adenocarcinoma: Discovery and evaluation of novel target candidates
Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells
Clinical immunotherapy in pancreatic cancer
Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma
Models of pancreatic ductal adenocarcinoma
Epigenetic control of pancreatic cancer metastasis
Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine
Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy
Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
Epigenetic regulation and role of metastasis suppressor genes in pancreatic ductal adenocarcinoma
Epigenetic regulation and role of metastasis suppressor genes in pancreatic ductal adenocarcinoma
Cellular immunotherapy of pancreatic ductal adenocarcinoma: Discovery and evaluation of novel target candidates
Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells
Clinical immunotherapy in pancreatic cancer
Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma
Models of pancreatic ductal adenocarcinoma
Epigenetic control of pancreatic cancer metastasis
Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine
Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy
Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
Epigenetic regulation and role of metastasis suppressor genes in pancreatic ductal adenocarcinoma
Epigenetic regulation and role of metastasis suppressor genes in pancreatic ductal adenocarcinoma
Cellular immunotherapy of pancreatic ductal adenocarcinoma: Discovery and evaluation of novel target candidates
Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells
Clinical immunotherapy in pancreatic cancer
Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma
Models of pancreatic ductal adenocarcinoma
Epigenetic control of pancreatic cancer metastasis